A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME
Clinical trial NCT06571045 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06571045
- Sponsor
- EyeBiotech Ltd.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-08-07
- Primary completion
- 2026-09-30
- Enrollment
- 984
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.